Teva Pharmaceutical Industries Ltd reports $4.39 billion revenue for quarter ended September 30, 2026, down 1.9%
Teva Pharmaceutical Industries Ltd reported revenue of $4.39 billion for the quarter ended September 30, 2026, a decrease of 1.9% from the same quarter a year earlier ($4.48 billion).
For the same period it posted net income of $233 million, down 46.2%, or $0.20 per diluted share (0.37 a year earlier).
That is a net margin of 5.3%.
On Sanad's AAOIFI Standard 21 screen, Teva Pharmaceutical Industries Ltd is currently not compliant: interest-bearing debt is 34% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).
Is Teva Pharmaceutical Industries Ltd halal?
See the full AAOIFI screening of Teva Pharmaceutical Industries Ltd
See the full AAOIFI screening of Teva Pharmaceutical Industries Ltd
Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 3, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.